Prof. Shilpa Chokshi
is a translational scientist in the field of hepatology, with research
interests that span viral hepatitis, alcoholic liver disease, the immune
mechanisms driving cirrhosis, and the development of immunotherapeutic
treatments for hepatocellular carcinoma. She currently holds the position of
Professor of Experimental Hepatology at King’s College London and serves as the
Acting Director and Chief Scientific Officer for the Roger Williams Institute
of Hepatology. Here, she leads an active research program, providing both
scientific and academic leadership. Prof. Shilpa
Chokshi’s research strategy is dedicated to “supporting
research into liver diseases that yield tangible clinical benefits for
patients” and she leads a research portfolio that encompasses a wide spectrum
of clinical manifestations of liver disease, all categorized under the umbrella
of “Mechanisms of Hepatic Injury and Repair”. The collective focus of these
studies is fundamental discovery-based studies to identify novel drug targets
and biomarkers, aimed at tackling the intricate challenges associated with
treating liver disorders.
Prof. Shilpa Chokshi
is a translational scientist in the field of hepatology, with research
interests that span viral hepatitis, alcoholic liver disease, the immune
mechanisms driving cirrhosis, and the development of immunotherapeutic
treatments for hepatocellular carcinoma. She currently holds the position of
Professor of Experimental Hepatology at King’s College London and serves as the
Acting Director and Chief Scientific Officer for the Roger Williams Institute
of Hepatology. Here, she leads an active research program, providing both
scientific and academic leadership. Prof. Shilpa
Chokshi’s research strategy is dedicated to “supporting
research into liver diseases that yield tangible clinical benefits for
patients” and she leads a research portfolio that encompasses a wide spectrum
of clinical manifestations of liver disease, all categorized under the umbrella
of “Mechanisms of Hepatic Injury and Repair”. The collective focus of these
studies is fundamental discovery-based studies to identify novel drug targets
and biomarkers, aimed at tackling the intricate challenges associated with
treating liver disorders.